Could Alzheimer’s actually be three different diseases?

Print Friendly, PDF & Email
Credit: Biospace
Credit: Biospace

Postmortem, RNA sequencing has revealed three major molecular subtypes of [Alzheimer’s] disease, each of which presents differently in the brain and which holds a unique genetic risk.

Such knowledge could help us predict who is most vulnerable to each subtype, how their disease might progress and what treatments might suit them best, potentially leading to better outcomes.

It could also help explain why effective treatments for AD have proved so challenging to find thus far.

Typically, accumulations of Aβ, [amyloid-beta plaques,] and NFT, [tau protein tangles,] are thought to drive neuronal and synaptic loss, predominantly within the cerebral cortex and hippocampus. Further degeneration then follows, including inflammation and degeneration of nerve cells’ protective coating, which causes signals in our brains to slow down.

Related article:  Video: What the lungs of newborns look like when they take their first breaths

Strangely enough, however, recent evidence has shown up to a third of patients with a confirmed, clinical diagnosis have no Aβ plaques in postmortem biopsies. What’s more, many of those found with plaques at death did not show cognitive impairment in life.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

In light of all this research, it’s highly likely there are specific subtypes of AD that we simply haven’t teased apart yet. The new research has helped unbraid three major strands.

Read the original post

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Trending green and going great — Every state in the US seeing decreased cases of COVID

Infographic: Trending green and going great — Every state in the US seeing decreased cases of COVID

The U.S. averaged fewer than 40,000 new cases per day over the past week. That’s a 21% improvement over the ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists